URGN Financial Statements

Balance sheet, income statement, cash flow, and dividends for Urogen Pharma Ltd (URGN).


$449.42M Market Cap.

As of 03/10/2025 5:00 PM ET (MRY) • Disclaimer

URGN Market Cap. (MRY)


URGN Shares Outstanding (MRY)


URGN Assets (MRY)


Total Assets

$285.71M

Total Liabilities

$294.51M

Total Investments

$69.90M

URGN Income (MRY)


Revenue

$90.40M

Net Income

-$126.87M

Operating Expense

$178.30M

URGN Cash Flow (MRY)


CF Operations

-$96.77M

CF Investing

-$20.61M

CF Financing

$194.62M

URGN Dividends (MRY)


Period

Dividends

Yield %

Growth %

Payout Ratio

Coverage Ratio

2024

$0

0%

0%

0%

-

2023

$0

0%

0%

0%

-

2022

$0

0%

0%

0%

-

2021

$0

0%

0%

0%

-

2020

$0

0%

-

0%

-

URGN Balance Sheet (MRY)


Metric

2024

2023

2022

2021

Total Assets

$285,711,000 (60.23%)

$178,311,000 (31.48%)

$135,619,000 (13.26%)

$119,746,000 (-1.85%)

Assets Current

$276,135,000 (63.21%)

$169,186,000 (31.25%)

$128,907,000 (12.69%)

$114,390,000 (-1.06%)

Assets Non-Current

$9,576,000 (4.94%)

$9,125,000 (35.95%)

$6,712,000 (25.32%)

$5,356,000 (-16.13%)

Goodwill & Intangible Assets

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Shareholders Equity

-$8,803,000 (86.50%)

-$65,212,000 (27.02%)

-$89,361,000 (-1162.18%)

$8,413,000 (-91.27%)

Property Plant & Equipment Net

$3,789,000 (60.55%)

$2,360,000 (-37.05%)

$3,749,000 (19.13%)

$3,147,000 (-25.14%)

Cash & Equivalents

$173,063,000 (80.61%)

$95,823,000 (70.44%)

$56,221,000 (23.33%)

$45,586,000 (-15.72%)

Accumulated Other Comprehensive Income

$56,000 (366.67%)

$12,000 (111.21%)

-$107,000 (-328.00%)

-$25,000 (-109.23%)

Deferred Revenue

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Total Investments

$69,896,000 (49.69%)

$46,693,000 (4.27%)

$44,779,000 (-1.97%)

$45,677,000 (-10.91%)

Investments Current

$64,698,000 (54.17%)

$41,966,000 (-5.81%)

$44,556,000 (-0.50%)

$44,779,000 (-8.90%)

Investments Non-Current

$5,198,000 (9.96%)

$4,727,000 (2019.73%)

$223,000 (-75.17%)

$898,000 (-57.56%)

Inventory

$9,227,000 (62.65%)

$5,673,000 (31.17%)

$4,325,000 (-10.49%)

$4,832,000 (146.03%)

Trade & Non-Trade Receivables

$20,302,000 (31.46%)

$15,443,000 (21.56%)

$12,704,000 (8.42%)

$11,717,000 (66.27%)

Trade & Non-Trade Payables

$27,431,000 (65.87%)

$16,538,000 (33.55%)

$12,383,000 (2.32%)

$12,102,000 (20.74%)

Accumulated Retained Earnings (Deficit)

-$806,222,000 (-18.68%)

-$679,348,000 (-17.72%)

-$577,104,000 (-23.49%)

-$467,321,000 (-31.09%)

Tax Assets

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Tax Liabilities

$3,791,000 (18.69%)

$3,194,000 (5.83%)

$3,018,000 (6.19%)

$2,842,000 (4.60%)

Total Debt

$123,387,000 (24.14%)

$99,395,000 (0.27%)

$99,123,000 (24805.28%)

$398,000 (-73.41%)

Debt Current

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Debt Non-Current

$123,387,000 (24.14%)

$99,395,000 (0.27%)

$99,123,000 (24805.28%)

$398,000 (-73.41%)

Total Liabilities

$294,514,000 (20.94%)

$243,523,000 (8.24%)

$224,980,000 (102.08%)

$111,333,000 (334.05%)

Liabilities Current

$45,949,000 (47.22%)

$31,212,000 (30.51%)

$23,916,000 (6.86%)

$22,380,000 (4.40%)

Liabilities Non-Current

$248,565,000 (17.08%)

$212,311,000 (5.59%)

$201,064,000 (126.03%)

$88,953,000 (2010.89%)

URGN Income Statement (MRY)


Metric

2024

2023

2022

2021

Revenues

$90,398,000 (9.29%)

$82,713,000 (28.52%)

$64,357,000 (33.96%)

$48,042,000 (307.17%)

Cost of Revenue

$8,881,000 (-5.13%)

$9,361,000 (22.30%)

$7,654,000 (48.42%)

$5,157,000 (411.10%)

Selling General & Administrative Expense

$121,154,000 (29.89%)

$93,274,000 (12.60%)

$82,838,000 (-5.37%)

$87,535,000 (-2.97%)

Research & Development Expense

$57,145,000 (25.28%)

$45,614,000 (-13.78%)

$52,906,000 (11.05%)

$47,642,000 (0.70%)

Operating Expenses

$178,299,000 (28.38%)

$138,888,000 (2.32%)

$135,744,000 (0.42%)

$135,177,000 (-1.71%)

Interest Expense

$12,521,000 (-14.91%)

$14,715,000 (74.39%)

$8,438,000 (0%)

$0 (0%)

Income Tax Expense

$2,832,000 (-27.76%)

$3,920,000 (123.36%)

$1,755,000 (21.12%)

$1,449,000 (-57.05%)

Net Loss Income from Discontinued Operations

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Consolidated Income

-$126,874,000 (-24.09%)

-$102,244,000 (6.87%)

-$109,783,000 (0.94%)

-$110,820,000 (13.75%)

Net Income to Non-Controlling Interests

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Income

-$126,874,000 (-24.09%)

-$102,244,000 (6.87%)

-$109,783,000 (0.94%)

-$110,820,000 (13.75%)

Preferred Dividends Income Statement Impact

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Income Common Stock

-$126,874,000 (-24.09%)

-$102,244,000 (6.87%)

-$109,783,000 (0.94%)

-$110,820,000 (13.75%)

Weighted Average Shares

$42,876,737 (48.70%)

$28,834,303 (26.43%)

$22,806,812 (2.06%)

$22,347,481 (2.60%)

Weighted Average Shares Diluted

$42,876,737 (48.70%)

$28,834,303 (26.43%)

$22,806,812 (2.06%)

$22,347,481 (2.60%)

Earning Before Interest & Taxes (EBIT)

-$111,521,000 (-33.38%)

-$83,609,000 (16.05%)

-$99,590,000 (8.94%)

-$109,371,000 (12.58%)

Gross Profit

$81,517,000 (11.13%)

$73,352,000 (29.36%)

$56,703,000 (32.22%)

$42,885,000 (297.45%)

Operating Income

-$96,782,000 (-47.68%)

-$65,536,000 (17.09%)

-$79,041,000 (14.36%)

-$92,292,000 (27.18%)

URGN Cash Flow Statement (MRY)


Metric

2024

2023

2022

2021

Net Cash Flow from Investing

-$20,613,000 (-2062.96%)

-$953,000 (-189.91%)

$1,060,000 (-73.95%)

$4,069,000 (-95.64%)

Net Cash Flow from Financing

$194,619,000 (66.44%)

$116,931,000 (20.38%)

$97,134,000 (34.31%)

$72,319,000 (337.58%)

Net Cash Flow from Operations

-$96,766,000 (-26.70%)

-$76,376,000 (12.77%)

-$87,559,000 (-3.14%)

-$84,892,000 (19.83%)

Net Cash Flow / Change in Cash & Cash Equivalents

$77,240,000 (95.04%)

$39,602,000 (272.37%)

$10,635,000 (225.06%)

-$8,504,000 (-319.23%)

Net Cash Flow - Business Acquisitions and Disposals

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Cash Flow - Investment Acquisitions and Disposals

-$20,318,000 (-2576.94%)

-$759,000 (-157.76%)

$1,314,000 (-72.74%)

$4,821,000 (-94.90%)

Capital Expenditure

-$295,000 (-52.06%)

-$194,000 (23.62%)

-$254,000 (66.22%)

-$752,000 (38.11%)

Issuance (Repayment) of Debt Securities

$24,488,000 (0%)

$0 (0%)

$95,783,000 (0%)

$0 (0%)

Issuance (Purchase) of Equity Shares

$170,131,000 (45.50%)

$116,931,000 (7638.65%)

$1,511,000 (2377.05%)

$61,000 (-99.63%)

Payment of Dividends & Other Cash Distributions

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Effect of Exchange Rate Changes on Cash

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Share Based Compensation

$13,108,000 (40.30%)

$9,343,000 (-11.69%)

$10,580,000 (-54.22%)

$23,113,000 (-17.53%)

Depreciation Amortization & Accretion

$1,186,000 (-30.44%)

$1,705,000 (-6.16%)

$1,817,000 (2.48%)

$1,773,000 (-13.26%)

URGN Financial Metrics (MRY)


Metric

2024

2023

2022

2021

Gross Margin

90.20% (1.69%)

88.70% (0.68%)

88.10% (-1.34%)

89.30% (-2.30%)

Profit Margin

-140.40% (-13.59%)

-123.60% (27.55%)

-170.60% (26.05%)

-230.70% (78.81%)

EBITDA Margin

-122.10% (-23.33%)

-99.00% (34.83%)

-151.90% (32.19%)

-224.00% (78.52%)

Return on Average Equity (ROAE)

-7363.60% (-6622.23%)

112.90% (-45.85%)

208.50% (181.22%)

-256.70% (-154.66%)

Return on Average Assets (ROAA)

-47.40% (32.77%)

-70.50% (7.48%)

-76.20% (13.11%)

-87.70% (-0.69%)

Return on Sales (ROS)

-123.40% (-22.06%)

-101.10% (34.65%)

-154.70% (32.06%)

-227.70% (78.52%)

Return on Invested Capital (ROIC)

-61.90% (-10.14%)

-56.20% (23.95%)

-73.90% (62.51%)

-197.10% (-50.69%)

Dividend Yield

0% (0%)

0% (0%)

0% (0%)

0% (0%)

Price to Earnings Ratio (P/E)

-3.6 (14.84%)

-4.22 (-129.12%)

-1.84 (3.81%)

-1.92 (37.23%)

Price to Sales Ratio (P/S)

5.05 (-3.40%)

5.23 (66.37%)

3.14 (-28.96%)

4.42 (-86.70%)

Price to Book Ratio (P/B)

-51.05 (-619.06%)

-7.1 (-209.77%)

-2.29 (-109.04%)

25.34 (513.36%)

Debt to Equity Ratio (D/E)

-33.46 (-795.98%)

-3.73 (-48.29%)

-2.52 (-119.03%)

13.23 (4874.81%)

Earnings Per Share (EPS)

-2.96 (16.62%)

-3.55 (26.20%)

-4.81 (3.02%)

-4.96 (15.93%)

Sales Per Share (SPS)

2.11 (-26.52%)

2.87 (1.67%)

2.82 (31.26%)

2.15 (296.68%)

Free Cash Flow Per Share (FCFPS)

-2.26 (14.76%)

-2.66 (31.01%)

-3.85 (-0.47%)

-3.83 (22.07%)

Book Value Per Share (BVPS)

-0.2 (90.94%)

-2.26 (42.27%)

-3.92 (-1142.02%)

0.38 (-91.50%)

Tangible Assets Book Value Per Share (TABVPS)

6.66 (7.76%)

6.18 (4.00%)

5.95 (10.97%)

5.36 (-4.34%)

Enterprise Value Over EBIT (EV/EBIT)

-4 (20.00%)

-5 (-66.67%)

-3 (-200.00%)

-1 (66.67%)

Enterprise Value Over EBITDA (EV/EBITDA)

-4.04 (25.29%)

-5.4 (-112.09%)

-2.55 (-74.21%)

-1.46 (51.91%)

Asset Turnover

0.34 (-40.70%)

0.57 (27.52%)

0.45 (17.63%)

0.38 (375.00%)

Current Ratio

6.01 (10.87%)

5.42 (0.58%)

5.39 (5.46%)

5.11 (-5.25%)

Dividends

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Free Cash Flow (FCF)

-$97,061,000 (-26.76%)

-$76,570,000 (12.80%)

-$87,813,000 (-2.53%)

-$85,644,000 (20.03%)

Enterprise Value (EV)

$445,355,759 (0.66%)

$442,416,800 (77.65%)

$249,036,646 (58.35%)

$157,270,291 (-57.96%)

Earnings Before Tax (EBT)

-$124,042,000 (-26.16%)

-$98,324,000 (8.98%)

-$108,028,000 (1.23%)

-$109,371,000 (12.58%)

Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

-$110,335,000 (-34.71%)

-$81,904,000 (16.23%)

-$97,773,000 (9.13%)

-$107,598,000 (12.57%)

Invested Capital

$190,086,000 (26.16%)

$150,671,000 (-2.54%)

$154,605,000 (196.30%)

$52,178,000 (8.76%)

Working Capital

$230,186,000 (66.83%)

$137,974,000 (31.42%)

$104,991,000 (14.11%)

$92,010,000 (-2.31%)

Tangible Asset Value

$285,711,000 (60.23%)

$178,311,000 (31.48%)

$135,619,000 (13.26%)

$119,746,000 (-1.85%)

Market Capitalization

$449,423,759 (-2.93%)

$462,994,800 (126.06%)

$204,808,646 (-3.94%)

$213,217,291 (-46.44%)

Average Equity

$1,723,000 (101.90%)

-$90,548,250 (-71.95%)

-$52,658,500 (-221.96%)

$43,178,000 (-66.13%)

Average Assets

$267,519,250 (84.41%)

$145,064,750 (0.75%)

$143,987,000 (13.93%)

$126,382,750 (-14.30%)

Invested Capital Average

$180,110,000 (21.12%)

$148,701,500 (10.27%)

$134,846,750 (142.96%)

$55,502,000 (-41.97%)

Shares

42,199,414 (36.72%)

30,866,320 (33.68%)

23,090,039 (2.99%)

22,420,325 (1.48%)